{"id":75678,"date":"2026-09-08T23:39:20","date_gmt":"2026-09-08T21:39:20","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/09\/08\/autologous-glypican-3-targeted-armored-car-t-cells-in-patients-with-advanced-solid-tumors-a-phase-1-dose-escalation-study-of-tak-102\/"},"modified":"2026-09-08T23:39:20","modified_gmt":"2026-09-08T21:39:20","slug":"autologous-glypican-3-targeted-armored-car-t-cells-in-patients-with-advanced-solid-tumors-a-phase-1-dose-escalation-study-of-tak-102","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/09\/08\/autologous-glypican-3-targeted-armored-car-t-cells-in-patients-with-advanced-solid-tumors-a-phase-1-dose-escalation-study-of-tak-102\/","title":{"rendered":"Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Sep 8. doi: 10.1158\/2326-6066.CIR-25-0855. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Chimeric antigen receptor (CAR) T-cell therapies have shown limited promise in solid tumors owing to the immunosuppressive tumor microenvironment. TAK-102 is a next-generation, glypican-3 (GPC3)-targeted CAR T-cell therapy engineered to co-express interleukin-7 (IL-7) and chemokine ligand 19 (CCL19), enhancing T-cell survival and trafficking. In this first-in-human, open-label, phase 1, dose-escalation study (ClinicalTrials.gov: NCT04405778), we evaluated a single TAK-102 infusion in 11 patients with GPC3+ advanced solid tumors refractory or intolerant to standard therapies. Patients received TAK-102 at one of three dose levels following leukapheresis and lymphodepletion chemotherapy. The primary endpoints were the incidences of dose-limiting toxicities, treatment-emergent adverse events, and adverse events of special interest. No dose-limiting toxicities were observed. The most common treatment-emergent adverse events were hematologic, including neutropenia and leukopenia (81.8%), and cytokine release syndrome (54.5%), all grade 1-2. No objective responses were observed; however, five patients achieved stable disease (disease control rate, 45.5%). One patient had a 26.1% reduction in tumor size lasting 9 months, accompanied by a 51.6% decline in serum alpha-fetoprotein. Cellular kinetics showed dose-dependent expansion, with the highest exposure at 5 \u00d7 10\u2078 CAR+ cells\/body. Post-treatment biopsies revealed increased CD8+ T-cell infiltration and activation markers, although CAR+ cells were undetectable in tumor tissue. Serum CCL19 levels increased with dose, suggesting immune priming. These findings support a manageable safety profile for TAK-102 and provide early evidence of biological activity in solid tumors. Further studies are warranted to optimize dosing, improve CAR T-cell persistence, and evaluate efficacy in larger patient cohorts.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42709571\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260908173920&amp;v=2.20.1\">42709571<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0855\">10.1158\/2326-6066.CIR-25-0855<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Sep 8. doi: 10.1158\/2326-6066.CIR-25-0855. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapies have shown limited promise in solid tumors owing to the immunosuppressive tumor microenvironment. TAK-102 is a next-generation, glypican-3 (GPC3)-targeted CAR T-cell therapy engineered to co-express interleukin-7 (IL-7) and chemokine ligand 19 (CCL19), enhancing T-cell survival and &#8230; <a title=\"Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/08\/autologous-glypican-3-targeted-armored-car-t-cells-in-patients-with-advanced-solid-tumors-a-phase-1-dose-escalation-study-of-tak-102\/\" aria-label=\"Read more about Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-75678","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/75678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=75678"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/75678\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=75678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=75678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=75678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}